Our results also indicate that ROS1 fusion NSCLCs show a beneficial ICI therapy response, which lessens in ROS1 G2032R resistance mutation, thus implying that driver genes should be considered when conducting anti-PD-L1/PD-1 ICI therapy to manage lung cancer treatment. Here, PDCD1 is linked to lung carcinoma.